Please use this identifier to cite or link to this item:
Title: A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures.
Austin Authors: Beran, R G;Berkovic, Samuel F ;Buchanan, N;Danta, G;Mackenzie, R;Schapel, G;Sheean, G;Vajda, F
Affiliation: Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Dec-1996
Publication information: Seizure; 5(4): 259-65
Abstract: The efficacy and tolerability of vigabatrin as add-on therapy was assessed in patients with uncontrolled partial seizures. Ninety-seven patients entered this seven-centre, double-blind, placebo-crossover study. Vigabatrin (2 g or 3 g) or placebo was administered daily. Vigabatrin was well-tolerated and did not cause clinically significant adverse drug effects when added to established anticonvulsant therapy. No significant differences were observed between dose groups for the overall incidence of adverse events, although drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities) showed a dose-related increase with vigabatrin treatment. The results of this study indicate that vigabatrin, given in a daily dose of either 2 g or 3 g is significantly more effective than placebo in reducing seizure frequency among patients with partial seizures.
Gov't Doc #: 8952010
Journal: Seizure
Type: Journal Article
Subjects: Adolescent
Anticonvulsants.administration & dosage.adverse effects
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Electroencephalography.drug effects
Epilepsy, Complex Partial.drug therapy
Middle Aged
Treatment Outcome
gamma-Aminobutyric Acid.administration & dosage.adverse effects.analogs & derivatives
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 17, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.